Claims
- 1. A compound selected from those of formula I ##STR12## in which Ar represents an aromatic residue such as, for example, a phenyl or heteroaryl ring, the phenyl ring being unsubstituted or substituted with one or more substituents chosen from C.sub.1-4 alkyl, Cl, F, Br, or C.sub.1-4 O-alkyl, n is one or two, thus forming an 8-azabicyclo-�3.2.1!octane or a 9-azabicyclo-�3.3.1!nonane,
- R.sub.1 is a linear or branched C.sub.1-6 alkyl group,
- R.sub.2 and R.sub.3, which may be identical or different, are H, Cl, Br, F, C.sub.1-4 alkyl, OH, CN, NO.sub.2, C.sub.1-4 S-alkyl, NH.sub.2, C.sub.1-4 NH-alkyl, C.sub.1-4 N-dialkyl, NH-acyl, SO.sub.2 NH.sub.2, C.sub.1-4 SO.sub.2 N-dialkyl or C.sub.1-4 SO.sub.2 -alkyl, and addition salts thereof with a pharmaceutically-acceptable inorganic or organic acid.
- 2. A compound of claim 1, wherein R.sub.1 is an methoxy or an ethoxy, R.sub.2 is Cl, Br, F, NH.sub.2, NMe.sub.2, OH, Ar, or a phenyl substituted with a halogen Cl or F.
- 3. A compound of claim 1, chosen from the group consisting of the following compounds and the addition salts thereof with a pharmaceutically-acceptable inorganic or organic acid:
- 1,3-dimethoxy-N-�8-(phenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 1-methoxy-N-�8-(phenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 4-bromo-1-methoxy-N-�8-(phenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 4-chloro-1-methoxy-N-�8-(phenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 1-methoxy-4-(N,N-dimethylamino)-N-�8-(phenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 4-amino-1-methoxy-N-�8-(phenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 1-methoxy-4-nitro-N-�8-(phenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 4-cyano-1-methoxy-N-�8-(phenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 1,5-dimethoxy-N-�8-(phenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 1,4-dimethoxy-N-�8-(phenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 1-ethoxy-N-�8-(phenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 4-bromo-1-ethoxy-N-�8-(phenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 4-acetamido-1-methoxy-N-�8-(phenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 4-acetamido-1-methoxy-N-�8-(4-fluorophenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 4-acetamido-1-methoxy-N-�8-(4-chlorophenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 4-amino-1-methoxy-N-�8-(4-chlorophenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 4-amino-1-methoxy-N-�8-(4-fluorophenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 4-amino-1-ethoxy-N-�8-(4-fluorophenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 4-fluoro-1-ethoxy-N-�8-(phenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 4-fluoro-1-methoxy-N-�8-(phenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 4-bromo-1-methoxy-N-�9-(phenylmethyl)-9-azabicyclo�3.3.1!non-3-b-yl!-2-naphthalenecarboxamide
- 4-amino-1-methoxy-N-�9-(phenylmethyl)-9-azabicyclo�3.3.1!non-3-b-yl!-2-naphthalenecarboxamide
- 4-bromo-1-methoxy-N-�8-(4-fluorophenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 4-bromo-1-methoxy-N-�8-(4-chlorophenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 4-methylthio-1-methoxy-N-�8-(phenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 4-ethylthio-1-methoxy-N-�8-(phenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 4-ethylsulfonyl-1-methoxy-N-�8-(phenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 4-aminosulfonyl!-1-methoxy-N-�8-(phenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 4-hydroxy-1-methoxy-N-�8-(phenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 4-hydroxy-1-ethoxy-N-�8-(phenylmethyl)-8-azabicyclo�3.2.1!oct-3-b-yl!-2-naphthalenecarboxamide
- 1-methoxy-N-�9-(phenylmethyl)-9-azabicyclo�3.3.1!non-3b-yl!-2-naphthalenecarboxamide
- 1-ethoxy-4-nitro-N-�8-(phenylmethyl)-8-azabicyclo�3.2.1!oct-3b-yl!-2-naphthalenecarboxamide.
- 4. Process for preparing a compound of formula I according to claim 1, wherein starting a naphthenic acid having the substituents R.sub.1, R.sub.2 and R.sub.3 according to claim 1 is reacted with 3.beta.-amino-8-benzyl!-8-azabicyclo�3.2.1!octane or 3.beta.-amino-9-benzyl!-9-azabicyclo�3.3.1!nonane under coupling conditions using alkyl chloroformate in the presence of triethylamine in methylene chloride at low temperature, or using the acid chloride of the corresponding starting naphthenic acid.
- 5. Pharmaceutical composition comprising at least one compound according to claims 1 and a pharmaceutically-acceptablr excipient.
- 6. Method for the treatment of a condition selected from schizophrenia, its positive and negative symptoms, compulsive obsessive disorders, anxiety, depression, drug addiction, tardive dyskinesia, and gastrointestinal disorders, comprising the step of administering to a living body suffering from such condition an amount of a compound of claim 1 which is effective for alleviation of such condition.
- 7. Pharmaceutical composition comprising at least one compound according to claim 2 and a pharmaceutically-acceptable excipient.
- 8. Pharmaceutical composition comprising at least one compound according to claim 3 and a pharmaceutically-acceptable excipient.
- 9. Method for the treatment of a condition selected from schizophrenia, its positive and negative symptoms, compulsive obsessive disorders, anxiety, depression, drug addiction, tardive dyskinesia, and gastrointestinal disorders, comprising the step of administering to a living body suffering from such condition an amount of a compound of claim 2 which is effective for alleviation of such condition.
- 10. Method for the treatment of a condition selected from schizophrenia, its positive and negative symptoms, compulsive obsessive disorders, anxiety, depression, drug addiction, tardive dyskinesia, and gastrointestinal disorders, comprising the step of administering to a living body suffering from such condition an amount of a compound of claim 3 which is effective for alleviation of such condition.
Priority Claims (1)
Number |
Date |
Country |
Kind |
95 10655 |
Sep 1995 |
FRX |
|
CROSS REFERENCE
The present application is a U.S. National Application filed under 35 USC 371 of PCT/FR96/01394, filed Sep. 11, 1996.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/FR96/01394 |
9/11/1996 |
|
|
3/12/1998 |
3/12/1998 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO97/10244 |
3/20/1997 |
|
|
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5395835 |
Glase |
Mar 1995 |
|
Foreign Referenced Citations (3)
Number |
Date |
Country |
0076592 |
Apr 1983 |
EPX |
0539281 |
Apr 1993 |
EPX |
0585116 |
Mar 1994 |
EPX |